NIH Deploys Picodya's B-Matrix In Vitro Diagnostics Platform to Detect Global Viral Threats
08 Jan 2024
Diagnostic ReagentsVaccineImmunotherapy
PREMISE Program, Led by NIAID, Ensures U.S. and Global Readiness for Future Pandemics
TEL AVIV, Israel, Jan. 8, 2024 /PRNewswire/ -- Picodya, creator of the first hybrid in vitro diagnostics (IVD) solution for multiplexed point-of-care testing (xPOCT), announced today the deployment of its B-Matrix™ technology in National Institutes of Health (NIH) laboratories. This deployment may enable large-scale global serologic surveillance with real-time monitoring of the immune status of human populations and detection of viral outbreaks, which could further the PREMISE goal of establishing a preemptive repository of candidate immunobiological countermeasures.
Picodya's B-Matrix™ platform is the first xPOCT IVD solution that performs both molecular and immunoassays from many body fluids on a singleplatform. The hybrid and scalable technology aims to deliver lab-comparable test results in a single patient encounter, considerably shortening the diagnostic timeline.
"With our knowledge of the devastating impact of Covid-19 on global health and following years of research collaboration with the NIH for crisis preparedness, we are proud to proceed with the next phase of this important partnership," said Tzvika Barkai, Founder and Chief Executive Officer at Picodya. "We remain dedicated to enabling timely, precise and comprehensive disease diagnosis capabilities to optimize potential outcomes. We plan to introduce the B-Matrix solution to additional research labs across the US, followed by the broader clinical market."
The NIH and its National Institute of Allergy and Infectious Diseases (NIAID)Infectious Diseases (NIAID) established PREMISE (Pandemic REsponse REpository through Microbial and Immune Surveillance and Epidemiology) in 2021 to prepare for pandemic outbreaks. PREMISE partnered with Picodya during initial phases of development to install the B-Matrix™ technology at NIAID Vaccine Research Center's (VRC) laboratories to detect reactivity to multiple potential pandemic threats. The program was presented by Daniel Douek, MD, Ph.D., to the White House Office of Science and Technology Policy in September 2021.
"Over the past two years, our team has established a global network of partner sites to meet the PREMISE objective of increasing immunologic monitoring of targeted human populations across the globe," said Dr. Daniel Douek, Chief, Human Immunology Section at NIH Vaccine Research Center; Director, PREMISE pandemic preparedness program and Picodya advisor. "We appreciate the significant benefits the B-Matrix™ platform could bring to the PREMISE program, enabling multiplex testing at scale with high accuracy. The platform is easy to operate and uses low sample volume, which therefore has the potential to accelerate effective discovery of new products for vaccine design, early development and clinical product testing."
Picodya conducted a feasibility analysis for the B-Matrix platform showing the system is suitable for performing dozens of immunoassays and molecular tests, including Covid-19, influenza, HBV, EBV, prostate cancer and cardiologic markers. The B-Matrix diagnostic system is currently being adopted by global research facilities to help streamline timelines and reduce costs. The company has initiated its regulatory pathway and following approval is expected to be available for use in a variety of healthcare settings and large-scale venues.
About Picodya
Picodya has developed the first in vitro diagnostics (IVD) multiplexed point-of-care testing platform that can perform both molecular and immunologic assays, in parallel, from many body fluids on a singular platform. The hybrid and scalable B-Matrix system automates sample preparation and provides lab-comparable results in a single patient encounter. The platform is being adopted by leading academic research institutions and pandemic preparedness programs in the US and Europe, and is designed for use in hospitals, physician offices, retail pharmacies and large-scale settings such as stadiums and airports. Founded in 2018 by Yehuda Yavets-Chen and Kibbutz Hatzerim, Picodya has raised $48 million to date. For more information, visit https://picodya.com/ and follow Picodya on LinkedIn.
Media Contact
Ellie Hanson
FINN Partners
[email protected]
SOURCE Picodya
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.